Equillium, Inc. EQ
We take great care to ensure that the data presented and summarized in this overview for Equillium, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EQ
View all-
Decheng Capital LLC Menlo Park, CA4.45MShares$2.22 Million0.49% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.45MShares$2.22 Million1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA824KShares$412,0450.0% of portfolio
-
Cota Capital Management, LLC San Francisco, CA562KShares$281,139100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny270KShares$134,7500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA196KShares$98,0450.0% of portfolio
-
Callan Capital, LLC La Jolla, CA99.7KShares$49,8440.0% of portfolio
-
State Street Corp Boston, MA59.7KShares$29,8600.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il55.6KShares$27,8240.0% of portfolio
-
Dcf Advisers, LLC Greenwich, CT39.5KShares$19,7460.01% of portfolio
Latest Institutional Activity in EQ
Top Purchases
Top Sells
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Insider Transactions at EQ
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2025
|
Jason A Keyes Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-20.96%
|
$0
$0.65 P/Share
|
|
Dec 10
2024
|
Jason A Keyes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+14.44%
|
$0
$0.54 P/Share
|
|
Nov 14
2024
|
Jason A Keyes Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-17.33%
|
$0
$0.7 P/Share
|
|
Oct 28
2024
|
Christine Zedelmayer Sr. Vice President and COO |
SELL
Open market or private sale
|
Direct |
15,000
-9.98%
|
$15,000
$1.25 P/Share
|
|
Oct 28
2024
|
Penny Tom Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,835
-30.26%
|
$2,835
$1.25 P/Share
|
|
Oct 25
2024
|
Penny Tom Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
683
-6.8%
|
$683
$1.25 P/Share
|
|
Sep 26
2024
|
Jason A Keyes Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-14.77%
|
$0
$0.81 P/Share
|
|
Sep 16
2024
|
Penny Tom Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
38,806
-79.43%
|
$0
$0.85 P/Share
|
|
Jul 16
2024
|
Jason A Keyes Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-12.87%
|
$0
$0.87 P/Share
|
|
Dec 08
2023
|
Jason A Keyes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,805
+13.0%
|
$0
$0.58 P/Share
|
|
Dec 08
2023
|
Christine Zedelmayer Sr. Vice President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
8,804
+6.11%
|
$0
$0.58 P/Share
|
|
Dec 08
2023
|
Joel Rothman Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,804
+13.15%
|
$0
$0.58 P/Share
|
|
Jun 09
2023
|
Jason A Keyes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+23.04%
|
$0
$0.56 P/Share
|
|
Jun 09
2023
|
Christine Zedelmayer Sr. Vice President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+10.61%
|
$0
$0.56 P/Share
|
|
Jun 09
2023
|
Joel Rothman Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+23.31%
|
$0
$0.56 P/Share
|
|
Dec 09
2022
|
Jason A Keyes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,444
+11.24%
|
$4,444
$1.19 P/Share
|
|
Dec 09
2022
|
Joel Rothman Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,821
+10.01%
|
$3,821
$1.19 P/Share
|
|
Aug 29
2022
|
Jason A Keyes Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
7,000
-8.26%
|
$14,000
$2.83 P/Share
|
|
Jun 10
2022
|
Christine Zedelmayer Sr. Vice President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
9,033
+7.5%
|
$9,033
$1.85 P/Share
|
|
Jun 10
2022
|
Joel Rothman Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,244
+16.98%
|
$6,244
$1.85 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 15K shares |
|---|
| Open market or private sale | 87.3K shares |
|---|